8 Rue Adrienne Bolland
6041 Gosselies, be
+44 (20) 7920-2333
State-of-the-art facility to support the manufacture of Bone Therapeutics' cell therapy products on a commercial scale
Production facility expected to be fully operational in 2015
Bone Therapeutics has made an investment in Skeletal Cell Therapy Support S.A (SCTS), alongside the Walloon region and private investors, to fund the €10 million construction of a new manufacturing facility based in the Gosselies Scientific Park near Brussels, Belgium. The financing of the building cost is fully secured in equal parts in equity, loans from ING and BNP Paribas Fortis and subsidies from the Walloon Region. Bone Therapeutics is now a 49.9% shareholder in SCTS. Skeletal Cell Therapy Support S.A will manage the construction and will run the site once operational.
This investment will allow Bone Therapeutics to manufacture its lead product PREOB®, an autologous bone cell therapy product currently in Phase III clinical trials for the treatment of osteonecrosis, under GMP conditions.
The construction of the new facility will also provide SCTS customers with state-of-the-art facilities tailored to meet the specific demands of the cell therapy industry and deliver long-term operational and financial efficiencies, with an improved manufacturing process at an increased scale. The completed production unit will initially include six class B production cells across 1.950m2 and will be able to produce up to 5.000 batches per annum at full capacity. In addition, 1.300m2 will be dedicated to quality control and research activities.
Upon completion of construction in 2015, Bone Therapeutics will be headquartered at the facility.
Enrico Bastianelli, Chief Executive Officer of Bone Therapeutics, commented: "We are delighted to be collaborating on this local venture to build a dedicated cell therapy industrial manufacturing facility in Wallonia. Securing access to these state of the art facilities is in line with Bone Therapeutics' strategy to become a successful commercial stage company and to support the potential commercialization of our lead product PREOB®, which is now ready for manufacturing and scale up. This is a great opportunity for Bone Therapeutics and we look forward to moving our operations into the brand new state-of-the-art facilities."
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an firstname.lastname@example.org.